205 related articles for article (PubMed ID: 9622081)
1. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate.
Li C; Yu DF; Newman RA; Cabral F; Stephens LC; Hunter N; Milas L; Wallace S
Cancer Res; 1998 Jun; 58(11):2404-9. PubMed ID: 9622081
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors.
Li C; Price JE; Milas L; Hunter NR; Ke S; Yu DF; Charnsangavej C; Wallace S
Clin Cancer Res; 1999 Apr; 5(4):891-7. PubMed ID: 10213226
[TBL] [Abstract][Full Text] [Related]
3. Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy.
Li C; Ke S; Wu QP; Tansey W; Hunter N; Buchmiller LM; Milas L; Charnsangavej C; Wallace S
Clin Cancer Res; 2000 Jul; 6(7):2829-34. PubMed ID: 10914731
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor.
Li C; Newman RA; Wu QP; Ke S; Chen W; Hutto T; Kan Z; Brannan MD; Charnsangavej C; Wallace S
Cancer Chemother Pharmacol; 2000; 46(5):416-22. PubMed ID: 11127947
[TBL] [Abstract][Full Text] [Related]
5. Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells.
Oldham EA; Li C; Ke S; Wallace S; Huang P
Int J Oncol; 2000 Jan; 16(1):125-32. PubMed ID: 10601557
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
7. Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability.
Milas L; Mason KA; Hunter N; Li C; Wallace S
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):707-12. PubMed ID: 12573758
[TBL] [Abstract][Full Text] [Related]
8. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel and water-soluble poly (L-glutamic acid)-paclitaxel, induce direct chromosomal abnormalities and cell death in a murine metastatic melanoma cell line.
Multani AS; Li C; Ozen M; Yadav M; Yu DF; Wallace S; Pathak S
Anticancer Res; 1997; 17(6D):4269-74. PubMed ID: 9494519
[TBL] [Abstract][Full Text] [Related]
10. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.
Auzenne E; Donato NJ; Li C; Leroux E; Price RE; Farquhar D; Klostergaard J
Clin Cancer Res; 2002 Feb; 8(2):573-81. PubMed ID: 11839679
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer.
Bonomi P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):415-22. PubMed ID: 17428162
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of water soluble poly(L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice.
Zou Y; Wu QP; Tansey W; Chow D; Hung MC; Charnsangavej C; Wallace S; Li C
Int J Oncol; 2001 Feb; 18(2):331-6. PubMed ID: 11172600
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of ovarian OCa-1 tumor radioresponse by poly (L-glutamic acid)-paclitaxel conjugate.
Li C; Ke S; Wu QP; Tansey W; Hunter N; Buchmiller LM; Milas L; Charnsangavej C; Wallace S
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1119-26. PubMed ID: 11072171
[TBL] [Abstract][Full Text] [Related]
14. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
17. Growth inhibition of a human ovarian tumor by a novel paclitaxel derivative in SCID mice.
Ahmad I; Masters GR; Schupsky JJ; Nguyen J; Ali S; Janoff AS; Mayhew E
Oncol Res; 1999; 11(6):273-80. PubMed ID: 10691029
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule.
Jang SH; Wientjes MG; Au JL
J Pharmacol Exp Ther; 2001 Mar; 296(3):1035-42. PubMed ID: 11181938
[TBL] [Abstract][Full Text] [Related]
19. 130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain.
Wiedenmann N; Valdecanas D; Hunter N; Hyde S; Buchholz TA; Milas L; Mason KA
Clin Cancer Res; 2007 Mar; 13(6):1868-74. PubMed ID: 17363543
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.
Singer JW
J Control Release; 2005 Dec; 109(1-3):120-6. PubMed ID: 16297482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
